Home / News / Hatchtech receives FDA special protocol agreement of DeOvo™ phase III studies and strengthens patent portfolio

Hatchtech receives FDA special protocol agreement of DeOvo™ phase III studies and strengthens patent portfolio

12 December 2013

Posted in — Media Release

Share

Learn More

Share

You may also like

18 June 2023

Vaxxas opens world-class manufacturing facility to produce needle-free vaccine patch

News, Announcement

30 March 2023

OneVentures pumps up artificial heart group BiVACOR

News, The Australian Financial Review

06 December 2022

Needle-free vaccine innovator banks $34m

News, The Australian Financial Review

10 November 2021

Vaxxas recognised in the Top 10 healthcare startups in Australia, 2021

News

View All

Ventured. Gained.

Subscribe to our Newsletter.

Name
decor
decor decor decor
decor decor decor decor decor